JAPAN

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue

Revenue contribution - by therapeutic category

to be negatively impacted by regulated price revisions and was valued at USD76 billion as at 31 December 2018

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

4

(2018: 9)^#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

Nil

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

13,9%

(2018: 12,8%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

^{^# The number of product launches has been restated to take into account discontinued operations.}

Revenue	2019 R'million	2018 (CER) R'million	change %
Total	2 124	2 119	0
Regional Brands	27	735	3
Sterile Focus Brands	1 364	1 384	(1)
Anaesthetics Brands	1 332	1 331	0
Thrombosis Brands	32	53	(40)